Login to Your Account



Pozen Record 0-2 In Migraine But Third Drug Is 'Good Shot'

By Randall Osborne


Monday, June 7, 2004

Casting a dark cloud over Memorial Day weekend for Pozen Inc. was word the Friday before from the FDA that its second migraine drug is not approvable. But Wall Street's thunder was not heard until Tuesday, when Pozen disclosed the news and saw more than 37 percent of its stock value wash away.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription